Online inquiry

IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8629MR)

This product GTTS-WQ8629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8629MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5436MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ12663MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ821MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11907MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ15621MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ3500MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ11821MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ485MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW